Home · Health · Sep 17 archive
FDA Approves First Gene Therapy for Sanfilippo Syndrome
Developing
In Short: The Food and Drug Administration has approved Fayuvi, a gene therapy for Sanfilippo syndrome type A, marking a significant milestone for patients with the ultra-rare disease.
The Food and Drug Administration on Thursday approved Fayuvi, a gene therapy for Sanfilippo syndrome type A, developed by Ultragenyx. This is the first drug specifically approved to treat Sanfilippo syndrome, an ultra-rare disease sometimes referred to as childhood Alzheimer’s.
Sanfilippo syndrome is a devastating genetic disorder that affects children, causing severe cognitive decline and early death. The approval of Fayuvi represents a major breakthrough for patients and their families.
Cara O’Neill, chief science officer of the Cure Sanfilippo Foundation, emphasized the significance of this approval. “It’s hard to overstate what this approval would mean for everybody who is living with this really horrific disease and watching their children suffer and pass away early,” she said.
The approval of Fayuvi marks a critical step in the treatment of Sanfilippo syndrome, offering hope to those affected by this debilitating condition.
Jason, a general assignment reporter with a focus on genetic medicine and rare diseases, noted that this development is a testament to ongoing advancements in gene therapy and rare disease research.
What's still developing
- You may opt out of receiving STAT communications at any time.
Sources
- STATlink